Satoshi Hirohata
Overview
Explore the profile of Satoshi Hirohata including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
117
Citations
1574
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Okubo S, Takaki A, Sato I, Adachi T, Takeuchi Y, Sue M, et al.
Intern Med
. 2025 Feb;
PMID: 39924239
Objective Identifying patients at high risk of steatotic liver disease (SLD) is crucial. The liver fibrosis stage is the most reliable marker of liver-related mortality. However, noninvasive risk stratification methods...
2.
Ohtsuki T, Sato I, Takashita R, Kodama S, Ikemura K, Opoku G, et al.
Int J Mol Sci
. 2024 Nov;
25(22).
PMID: 39596012
Osteoarthritis (OA) is a chronic disease affecting over 500 million people worldwide. As the population ages and obesity rates rise, the societal burden of OA is increasing. Pro-inflammatory cytokines, particularly...
3.
Sano M, Yamaji H, Higashiya S, Kubo M, Murakami T, Kawamura H, et al.
J Cardiovasc Electrophysiol
. 2024 Jul;
35(9):1839-1846.
PMID: 39049491
Background: Maintaining an adequate temperature at the target site is essential for effective ablation. We hypothesized that a tissue temperature-controlled (T-Con) catheter for cavotricuspid isthmus (CTI) ablation could improve the...
4.
Honma K, Kirihara S, Nakayama H, Fukuoka T, Ohara T, Kitamori K, et al.
Exp Biol Med (Maywood)
. 2023 Aug;
248(13):1112-1123.
PMID: 37646078
Non-alcoholic steatohepatitis (NASH) is a progressive form of non-alcoholic fatty liver disease (NAFLD) that causes cirrhosis and hepatocellular carcinoma. Iron is an essential trace element in the body; however, excess...
5.
Akagi S, Nakamura K, Kondo M, Hirohata S, Udono H, Nishida M, et al.
J Clin Med
. 2023 Aug;
12(15).
PMID: 37568430
Background: The metabolic state of pulmonary artery smooth muscle cells (PASMCs) from patients with pulmonary arterial hypertension (PAH) is not well understood. In this study, we examined the balance between...
6.
Kakimoto M, Fujii M, Sato I, Honma K, Nakayama H, Kirihara S, et al.
J Appl Biomed
. 2023 Jun;
21(2):80-90.
PMID: 37376883
Background: Xanthine oxidase (XO) generates reactive oxygen species during uric acid production. Therefore, XO inhibitors, which suppress oxidative stress, may effectively treat non-alcoholic steatohepatitis (NASH) and atherosclerosis via uric acid...
7.
Yamamoto S, Sato I, Fujii M, Kakimoto M, Honma K, Kirihara S, et al.
Can J Physiol Pharmacol
. 2023 May;
101(9):455-465.
PMID: 37224568
The liver X receptor (LXR) can enhance cholesterol transporters, which could remove excess cholesterol from foam cells in atheromas. LXR has two subtypes: LXRα, which aggravates hepatic lipid accumulation, and...
8.
Yamamoto S, Honma K, Fujii M, Kakimoto M, Kirihara S, Nakayama H, et al.
Ann Anat
. 2023 May;
249:152104.
PMID: 37209870
Background: Secondary sarcopenia develops as a result of a bedridden state and illnesses, such as cachexia, liver disease, and diabetes. However, there is a lack of animal models to investigate...
9.
Yamamoto S, Sato I, Fujii M, Kakimoto M, Honma K, Akiyama N, et al.
Acta Med Okayama
. 2023 Feb;
77(1):29-36.
PMID: 36849143
The SHRSP5/Dmcr is a useful animal model for the development of nonalcoholic steatohepatitis (NASH) pathology when fed a high-fat, high-cholesterol diet, and further drug interventions can lead to concomitant cardiovascular...
10.
Matsuzaki M, Yokoyama M, Yoshizawa Y, Kaneko N, Naito H, Kobayashi H, et al.
Mol Psychiatry
. 2023 Jan;
28(4):1802-1812.
PMID: 36721026
Amyloid-β (Aβ) deposition in the brain parenchyma is one of the pathological hallmarks of Alzheimer disease (AD). We have previously identified amyloid precursor protein (APP)669-711 (a.k.a. Aβ(-3)-40) in human plasma...